A total of 86 individuals were recruited: 36 with COPD and normal AAT levels, 20 patients with COPD and AATD (Pi*ZZ), of whom 11 were on augmentation therapy, and 30 healthy controls. The gene discussed is SERPINA1; the disease is alpha 1-antitrypsin deficiency.